PID1: Key Regulator of Immune Response and Potential Drug Target Or Biomarker

Target Name: PID1

NCBI ID: G55022

PID1

PID1: Key Regulator of Immune Response and Potential Drug Target Or Biomarker

PID1 (P-CLI1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the immune response and has been implicated in a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. While the exact function of PID1 is not yet fully understood, it is clear that it plays an important role in the regulation of immune responses and has potential as a drug target or biomarker.

PID1 function and localization:

PID1 is a member of the PID family of proteins, which includes PID4 and PID5. These proteins are involved in the regulation of inflammation and immune responses. PID1 is characterized by a single transmembrane domain and a N-terminus that contains a putative F-calcium-binding site. It is also known to have a C-terminal tail that is involved in protein-protein interactions and may play a role in PID1's localization to its downstream targets.

PID1 localization to different tissues and organs:

PID1 is expressed in a variety of tissues and organs, including the brain, heart, and kidneys. In the brain, PID1 is found in the outer layers of neurons and is thought to play a role in the regulation of synaptic plasticity and neurotransmitter release. In the heart, PID1 is expressed in the cardiac muscle and is involved in the regulation of contractility and arrhythmia. In the kidneys, PID1 is found in the podocytes and is involved in the regulation of water and electrolyte balance.

PID1's role in immune responses:

PID1 is involved in the regulation of the immune response by controlling the movement of immune cells into the tissue and by regulating the production of pro-inflammatory cytokines. It is known to interact with the transcription factor NF-kappa-B and the protein PD-L1, which are involved in the regulation of immune responses. PID1 has been shown to play a role in the regulation of T-cell proliferation and the production of antibodies.

PID1's potential as a drug target or biomarker:

The potential of PID1 as a drug target or biomarker is due to its involvement in the regulation of immune responses and its role in the development of autoimmune diseases. PID1 has been shown to play a role in the regulation of inflammation and has been implicated in the development of neurodegenerative disorders. Additionally, PID1 has been shown to be involved in the regulation of cancer cell growth and has potential as a biomarker for cancer diagnosis and treatment.

Conclusion:

PID1 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of the immune response. While the exact function of PID1 is not yet fully understood, its involvement in the regulation of immune responses and its potential as a drug target or biomarker make it a promising target for future research. Further studies are needed to fully understand the role of PID1 in the regulation of immune responses and its potential as a drug target or biomarker.

Protein Name: Phosphotyrosine Interaction Domain Containing 1

Functions: Increases proliferation of preadipocytes without affecting adipocytic differentiation

The "PID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets